Furthermore, crizotinib-treated cells lost their sphere-forming abilities in a dose-dependent manner, suggesting that crizotinib at least partially inhibits features of stemness in EML4-ALK+ NSCLC cells [81]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.